UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000019483
Receipt number R000022527
Scientific Title The development of treatment using neurofeedback for patients with mood disorder: an exploratory study through neuroimaging approaches
Date of disclosure of the study information 2015/10/23
Last modified on 2023/10/30 08:23:44

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The development of treatment using neurofeedback for patients with mood disorder: an exploratory study through neuroimaging approaches

Acronym

The development of treatment using neurofeedback (NFB) for patients with mood disorder

Scientific Title

The development of treatment using neurofeedback for patients with mood disorder: an exploratory study through neuroimaging approaches

Scientific Title:Acronym

The development of treatment using neurofeedback (NFB) for patients with mood disorder

Region

Japan


Condition

Condition

Mood disorders (major depressive disorder and bipolar disorder) and healthy volunteers

Classification by specialty

Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to identify the changes in brain activity following NFB interventions against patients with mood disorder and to explore novel methodological approaches that effectively improve treatment effect.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Using psychological assessments and neuroimaging techniques, we evaluate psychological and neural changes in depression-related symptoms, immediately after the intervention, one week later, one month later, and again six months later.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

For depressive patients, conducting NFB training to control regional brain activities associated with major depressive disorder or to improve higher cognitive functions, such as attention and working memory, whose improvement are thought to be effective against mood disorders

Interventions/Control_2

For healthy-control individuals, establish feasibility of neurofeedback training to control regional activities associated with mood disorders. In addition, examining potentials as an alternative medicine of NFB training on cognitive functions such as attention and working memory whose improvement are thought to be effective against mood disorders.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

For patients/clients
1) Aged 20-0 years old
2) Being diagnosed as major depressive disorder or bipolar disorder (Type I, Type II) according to DSM-IV-TR or DSM-5 criteria
3) Present ongoing episode of major depressive symptoms
4) Present treatment-resistance (scores 14 points or above out of 17 items on the Hamilton Rating Scale for Depression even after >=4 weeks of treatment with sufficient amount of more than 1 anti-depressant) or low treatment-tolerance (insufficient administration due to side-effects while taking more than 1 anti-depressant)
5) Satisfactory informed consent obtained from the participant him/herself
For healthy control
1) Aged 20-80 years old
2) Not history of psychiatric disorders
3) Not having current serious medical illness
Satisfactory informed consent obtained from the participant him/herself

Key exclusion criteria

1) Decisionally impaired individuals who has diminished capacity to understand the aim of the research
2) Physically impaired individuals who are not able to complete the experiment
3) Subjects who are contraindicated for the use of MRI
Having an implanted heart pace-maker
Having implanted cerebral (arteries) clips
Having implanted neural/nerve stimulators
Having implanted pumps
Having work experience in a metal industry or possibility of metal residues remaining in the body
Having metal-tattoos (including tattooed eye-lining)
Being pregnant, or having possibility of being pregnant
4) Any individuals judged as inappropriate for the experiment by the principal investigator or a collaborating researcher

Target sample size

210


Research contact person

Name of lead principal investigator

1st name Go
Middle name
Last name Okada

Organization

Graduate school of Biomedical and Health Sciences, Hiroshima University

Division name

Department of Psychiatry and Neurosciences

Zip code

734-8551

Address

1-2-3 Kasumi, Minamiku, Hiroshima, 734-8553, Japan

TEL

082-257-5205

Email

goookada@hiroshima-u.ac.jp


Public contact

Name of contact person

1st name Go
Middle name
Last name Okada

Organization

Graduate school of Biomedical and Health Sciences, Hiroshima University

Division name

Department of Psychiatry and Neurosciences

Zip code

734-8551

Address

1-2-3 Kasumi, Minamiku, Hiroshima, 734-8553, Japan

TEL

082-257-5814

Homepage URL


Email

goookada@hiroshima-u.ac.jp


Sponsor or person

Institute

Department of Psychiatry and Neurosciences, Graduate school of Biomedical and Health Sciences, Hiroshima University

Institute

Department

Personal name



Funding Source

Organization

AMED

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethical Committee for Clinical Research of Hiroshima University

Address

1-2-3 Kasumi, Minamiku, Hiroshima

Tel

082-257-1551

Email

iryo-seisaku@office.hiroshima-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 10 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2015 Year 10 Month 20 Day

Date of IRB


Anticipated trial start date

2015 Year 11 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 10 Month 23 Day

Last modified on

2023 Year 10 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022527


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name